摘要
在临床研究中,总生存期(OS)已作为评价肝癌疗效的指标。但OS的观察时间长,且受到后续治疗的影响,一些相关替代终点应运而生。经导管动脉化疗栓塞(TACE)与靶免药物在治疗肝细胞癌(HCC)患者时,其适用人群、治疗周期及疗效方面都存在较大差异,因此有必要针对TACE相关研究选择合适的替代终点。本文对TACE治疗肝癌后各替代终点进行归纳和分析,为替代终点的选择提供参考。
In clinical studies, the overall survival(OS) has been used as an index for evaluating the curative efficacy of hepatocellular carcinoma(HCC). However, the observation time of OS is long and it is easily affected by subsequent treatments, because of which several relevant surrogate endpoints have been emerged. In treating patients with HCC, the applicable population, treatment cycle and curative efficacy of transcatheter arterial chemoembolization(TACE) and targeted immunotherapy drugs are greatly different, so it is necessary to choose appropriate surrogate endpoints for TACE-related studies. This paper summarizes and analyzes each surrogate endpoint after TACE treatment of HCC so as to provide a reference for the selection of surrogate endpoints.(J Intervent Radiol, 2022, 31: 728-732)
作者
史逸恺
倪才方
SHI Yikai;NI Caifang(Department of Interventional Radiology,First Afiliated Hospial of Soochow University,Suzhou,Jiangsu Province215006,China)
出处
《介入放射学杂志》
CSCD
北大核心
2022年第7期728-732,共5页
Journal of Interventional Radiology
关键词
经导管动脉化疗栓塞
替代终点
肝细胞癌
transcatheter arterial chemoembolization
surrogate endpoint
hepatocellular carcinoma
